Articles with public access mandates - Bhushan PattniLearn more
Not available anywhere: 2
New developments in liposomal drug delivery
BS Pattni, VV Chupin, VP Torchilin
Chemical reviews 115 (19), 10938-10966, 2015
Mandates: US National Institutes of Health
Combination Nanopreparations of a Novel Proapoptotic Drug–NCL-240, TRAIL and siRNA
R Riehle, B Pattni, A Jhaveri, A Kulkarni, G Thakur, A Degterev, ...
Pharmaceutical research 33, 1587-1601, 2016
Mandates: US National Institutes of Health
Available somewhere: 5
Nanopreparations to overcome multidrug resistance in cancer
NR Patel, BS Pattni, AH Abouzeid, VP Torchilin
Advanced drug delivery reviews 65 (13-14), 1748-1762, 2013
Mandates: US National Institutes of Health
Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma
A Jhaveri, P Deshpande, B Pattni, V Torchilin
Journal of controlled release 277, 89-101, 2018
Mandates: US National Institutes of Health
Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer
P Deshpande, A Jhaveri, B Pattni, S Biswas, V Torchilin
Drug delivery 25 (1), 517-532, 2018
Mandates: US National Institutes of Health
Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG
BS Pattni, A Jhaveri, I Dutta, JD Baleja, A Degterev, V Torchilin
International journal of pharmaceutics 532 (1), 149-156, 2017
Mandates: US National Institutes of Health
Targeting of micelles and liposomes loaded with the pro-apoptotic drug, NCL-240, into NCI/ADR-RES cells in a 3D spheroid model
BS Pattni, SG Nagelli, B Aryasomayajula, PP Deshpande, A Kulkarni, ...
Pharmaceutical research 33, 2540-2551, 2016
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program